Come on finish 1.60 plus, page-352

hey thomb

Me too. I researched the three stock.
I found ARX and PNV the most promising.
AvH was loosing too much money a year currently and a lot more cash raises coming for that one.
You'd think ARX was better value; if you looked at it's 82 vs 47% growth, more products for sale, the Ovitex with Tela Bio kicking goals in the US, they have guidance this next FY PNV didn't, lots of staff in US to support expansion and more cash in the bank.

But I went with PNV; here is why;

integra is the gold standard of care in the US and arguably globally. It's a biologic. Porcine. ARX is also biologic. It's sheep. ARX claim to be significantly cheaper, but I've not seen any independent journals suggesting how much by or even if it is. It's growth in sales would suggest so.
I didn't like the cash burn of ARX. PNV even though less cash in bank is much more profitable and only loosing 1 million this year. The big thing is margin. PnV is 96% margin and improving. ARX was 70% now 76% and improving with its new products. However this is where things get interesting. PNV is by far the cheapest option and it's performs beats Intwgra on every front. Less infections lower cost and aesethically better appearance. On margins if PNV halve it's prices it can still be making 90% margin; but the impact this would have on ARX and Integra which are already more expensive to make (lower margin) and higher priced would result Ina drastic reduction in margin to these companies. Thinking along the lines of margin falling from 76 to 30% quite easily. So PNV is the clear dominant winner due to its much lower cost of production.

Pnv is the only synthetic on the market (so it has no synthetic competition. Very easy for a sales person to sell that story. Whereas ARX need to sell the story of choosing one biologic over another. And that's tough. Pigs are being tested now where they are being modified at embryo with human phenotype to have a pig that's got a mixture of pig and human DNA; for organ transplant these organs are then accepted more so like O blood types. So I can't see use of pigs going away for medical applications.

Leadership; ARX are kicking goals;but the strength of PNV new CEO and their new Scientific Officer blitz ARX all day long. Strategically PNV have a better leadership team to strategically grow PNV.

I think both companies have a strong future. But if someone like Barda need to make a choice as to which product to stockpile for US emergency a a synthetic has a much longer shelf life over any biologic.

PnVs but weakness IMHO at the moment is they cannot get their distributors firing. Growth of sales in them is dismal. But that could turn around drastically if they start changing distributors which is very easily done.
i forecast both companies to grow 50-60% this year which in healthcare is high growth.
its a buy for both for me, but I hold PNV for now. Better more experienced glob management and the only synthetic on market will trump in the long term imho.
Pnv has about 5-10 times more independent journal articles too. Lots of doctors are writing on it. Not so much with Aroa yet.
Not a good look when the white volcano disaster in NZ, and Emergency depts there/ surgeons chose Polynovo, an Aussie company over Aroa, a NZ company. What's that tell you?